Drug Profile
Research programme: oncolytic immunotherapies - Replimune
Alternative Names: RP3 SeriesLatest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Replimune
- Class Antineoplastics; Immunotherapies; Oncolytic viruses
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Cancer in USA (Intratumoural, Injection)
- 07 Aug 2020 Replimune plans a phase I trial for RP 3 (Monotherapy, Combination therapy) for Cancer in 2020
- 03 Jun 2020 Replimune has patent protection for Immulytic™ platform in the US